Trial Outcomes & Findings for Angiotensin II for Distributive Shock (NCT NCT04904562)

NCT ID: NCT04904562

Last Updated: 2026-04-13

Results Overview

Total catecholamine dose for first 24 hours after distributive shock is first diagnosed

Recruitment status

TERMINATED

Study phase

PHASE4

Target enrollment

2 participants

Primary outcome timeframe

24 hours

Results posted on

2026-04-13

Participant Flow

Only 2 participants were enrolled in this study. Based on the low enrollment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

Participant milestones

Participant milestones
Measure
Treatment
Angiotensin II administered as an intravenous (IV) infusion will be increased every 5 minutes by 5-10ng/kg/min increments up to 80ng/kg/min Angiotensin II: Angiotensin II started at 5 ng/kg/min and titrated in 5-10 ng/kg/min increments every 5 minutes up to 80ng/kg/min to achieve target arterial pressure (MAP)
Control
Intravenous (IV) infusion (saline) Placebo: Placebo
Overall Study
STARTED
1
1
Overall Study
COMPLETED
1
1
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Angiotensin II for Distributive Shock

Baseline characteristics by cohort

Baseline data not reported

PRIMARY outcome

Timeframe: 24 hours

Population: Only 2 participants were enrolled in this study. Based on the low enrollment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

Total catecholamine dose for first 24 hours after distributive shock is first diagnosed

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 24 hours

Population: Only 2 participants were enrolled in this study. Based on the low enrollment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

Cumulative time spent with MAP \< 70 mmHg within the first 24 hours after distributive shock is first diagnosed

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 24 hours

Population: Only 2 participants were enrolled in this study. Based on the low enrollment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

Time to extubation after arrival in the ICU if distributive shock is diagnosed intraoperatively or time to extubation after distributive shock is diagnosed postoperatively

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 48 hours

Population: Only 2 participants were enrolled in this study. Based on the low enrollment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

Incidence of stroke confirmed by neurologist within 48 hours after distributive shock is first diagnosed

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 48 hours

Population: Only 2 participants were enrolled in this study. Based on the low enrollment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

Incidence of acute kidney injury, staged by KDIGO Creatinine criteria, within 48 hours after distributive shock is first diagnosed

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 24 hours

Population: Only 2 participants were enrolled in this study. Based on the low enrollment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

Incidence of new tachyarrhythmia within the first 24 hours after distributive shock is first diagnosed

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 24 hours

Population: Only 2 participants were enrolled in this study. Based on the low enrollment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

Units of blood transfused within first 24 hours after distributive shock is first diagnosed

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 24 hours

Population: Only 2 participants were enrolled in this study. Based on the low enrollment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

Fluid overload within the first 24 hours after distributive shock is first diagnosed

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 1 year

Population: Only 2 participants were enrolled in this study. Based on the low enrollment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

Total time spent in the ICU after initial diagnosis of distributive shock

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 1 year

Population: Only 2 participants were enrolled in this study. Based on the low enrollment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

Total time spent in the hospital after diagnosis of distributive shock

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 30 days

Population: Only 2 participants were enrolled in this study. Based on the low enrollment number, no data is reported here in order to protect and maintain participant privacy/confidentiality.

Subject death within 30 days of diagnosis of distributive shock

Outcome measures

Outcome data not reported

Adverse Events

Treatment

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Choy Lewis

Northwestern University

Phone: (312) 695-0061

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place